{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:05:34Z","timestamp":1779318334136,"version":"3.51.4"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die in der Diabetes-Klassifikation als Typ-3-Diabetes beschriebenen Krankheitsentit\u00e4ten umfassen andere spezifische Diabetesformen, welche pathophysiologisch und therapeutisch eine sehr heterogene Krankheitsgruppe darstellen. Diese beinhalten Formen, die aufgrund von genetischen Erkrankungen (monogenetische Formen, neonataler Diabetes, Down-Syndrom, Klinefelter-Syndrom, Turner-Syndrom) oder im Rahmen anderer endokrinologischer Erkrankungen auftreten (z.\u202fB. Akromegalie, Cushing-Syndrom, Glukagonom), sowie die an H\u00e4ufigkeit und Komplexit\u00e4t zunehmenden medikament\u00f6s induzierten Diabetesformen (z.\u202fB. Therapie mit Glukokortikoiden, Immun-Checkpoint-Inhibitoren, Calcineurininhibitoren, Phosphatidylinositol-3-Kinase-Inhibitoren, hochaktive antiretrovirale Therapie [HAART], Antipsychotika). Ebenfalls in diese Diabeteskategorie fallen pankreoprive Formen (z.\u202fB. postoperativ, Zustand nach Pankreatitis, Pankreastumoren, H\u00e4mochromatose, zystische Fibrose), seltener infektionsgetriggerte (z.\u202fB. kongenitale R\u00f6telninfektion) oder autoimmune Formen (z.\u202fB. Stiffman-Syndrom, Anti-Insulin-Rezeptor-Antik\u00f6rper, Insulin-Autoimmunsyndrom). Die korrekte Zuordnung des Diabetestyps hat unmittelbare therapeutische Auswirkungen f\u00fcr die Betroffenen. Zus\u00e4tzlich findet sich nicht nur bei pankreopriven Formen, sondern auch bei Diabetes mellitus Typ\u00a01\u00a0oder langj\u00e4hrigem Typ-2-Diabetes mellitus h\u00e4ufig eine Assoziation mit einer exokrinen Pankreasinsuffizienz.<\/jats:p>","DOI":"10.1007\/s00508-025-02653-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:14:34Z","timestamp":1779315274000},"page":"272-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetische, endokrine, medikament\u00f6se und pankreoprive Diabetesformen und exokrine Pankreasinsuffizienz (Update 2026)","Genetic, endocrine, drug-induced and pancreatogenic forms of diabetes and exocrine pancreatic insufficiency (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Susanne","family":"Kaser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine E.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Kazemi-Shirazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stulnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Winhofer-St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Ress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlies","family":"Treiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Szodl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Radlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"8","key":"2653_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2337\/dc11-0035","volume":"34","author":"SS Fajans","year":"2011","unstructured":"Fajans\u00a0SS, Bell\u00a0GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34(8):1878\u201384.","journal-title":"Diabetes Care"},{"issue":"170","key":"2653_CR2","first-page":"339","volume":"43","author":"RB Tattersall","year":"1974","unstructured":"Tattersall\u00a0RB. Mild familial diabetes with dominant inheritance. Q\u00a0J Med. 1974;43(170):339\u201357.","journal-title":"Q J Med"},{"issue":"9","key":"2653_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jdi.13860","volume":"13","author":"M Tosur","year":"2022","unstructured":"Tosur\u00a0M, Philipson\u00a0LH. Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY). J\u00a0Diabetes Investig. 2022;13(9):1465\u201371.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2653_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1210\/clinem\/dgaa710","volume":"106","author":"DT Broome","year":"2021","unstructured":"Broome\u00a0DT, Pantalone\u00a0KM, Kashyap\u00a0SR, Philipson\u00a0LH. Approach to the patient with MODY-monogenic diabetes. J\u00a0Clin Endocrinol Metab. 2021;106(1):237\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2653_CR5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1007\/s00125-010-1799-4","volume":"53","author":"BM Shields","year":"2010","unstructured":"Shields\u00a0BM, Hicks\u00a0S, Shepherd\u00a0MH, Colclough\u00a0K, Hattersley\u00a0AT, Ellard\u00a0S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504\u20138.","journal-title":"Diabetologia"},{"issue":"10","key":"2653_CR6","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1210\/jc.2013-1279","volume":"98","author":"C Pihoker","year":"2013","unstructured":"Pihoker\u00a0C, Gilliam\u00a0LK, Ellard\u00a0S, et\u00a0al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J\u00a0Clin Endocrinol Metab. 2013;98(10):4055\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2653_CR7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/dc16-0645","volume":"39","author":"M Shepherd","year":"2016","unstructured":"Shepherd\u00a0M, Shields\u00a0B, Hammersley\u00a0S, et\u00a0al. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5\u202f% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care. 2016;39(11):1879\u201388.","journal-title":"Diabetes Care"},{"key":"2653_CR8","doi-asserted-by":"publisher","first-page":"4616903","DOI":"10.1155\/2023\/4616903","volume":"2023","author":"K Nagl","year":"2023","unstructured":"Nagl\u00a0K, Waldhor\u00a0T, Hofer\u00a0SE, et\u00a0al. Ongoing Increase in Incidence of Diabetes in Austrian Children and Adolescents (1989\u20132021): Results from a\u00a0Nationwide Registry. Pediatr Diabetes. 2023;2023:4616903.","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"2653_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00125-011-2090-z","volume":"54","author":"J Kropff","year":"2011","unstructured":"Kropff\u00a0J, Selwood\u00a0MP, McCarthy\u00a0MI, Farmer\u00a0AJ, Owen\u00a0KR. Prevalence of monogenic diabetes in young adults: a\u00a0community-based, cross-sectional study in Oxfordshire, UK. Diabetologia. 2011;54(5):1261\u20133.","journal-title":"Diabetologia"},{"issue":"8","key":"2653_CR10","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s13300-020-00864-4","volume":"11","author":"M Delvecchio","year":"2020","unstructured":"Delvecchio\u00a0M, Pastore\u00a0C, Giordano\u00a0P. Treatment Options for MODY Patients: A\u00a0Systematic Review of Literature. Diabetes Ther. 2020;11(8):1667\u201385.","journal-title":"Diabetes Ther"},{"issue":"5","key":"2653_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00125-017-4226-2","volume":"60","author":"AT Hattersley","year":"2017","unstructured":"Hattersley\u00a0AT, Patel\u00a0KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):769\u201377.","journal-title":"Diabetologia"},{"key":"2653_CR12","doi-asserted-by":"crossref","unstructured":"Cobry EC, Steck AK. Review of Monogenic Diabetes: Clinical Features and Precision Medicine in Genetic Forms of Diabetes. Diabetes Technol Ther. 2025;.","DOI":"10.1089\/dia.2024.0602"},{"issue":"1","key":"2653_CR13","first-page":"596","volume":"66","author":"ML Sharp l","year":"2023","unstructured":"Sharp l\u00a0ML, Colclough\u00a0K, Haley\u00a0J, Hattersley\u00a0A, Carey\u00a0D, Weedon\u00a0M, Patel\u00a0K. MODY in older onset diabetes is common and identification can improve treatment: analysis of \u3009\u202f72,000 people. Diabetologia. 2023;66(1):596\u20137.","journal-title":"Diabetologia"},{"issue":"4","key":"2653_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/dme.12314","volume":"31","author":"J Urbanova","year":"2014","unstructured":"Urbanova\u00a0J, Rypackova\u00a0B, Prochazkova\u00a0Z, et\u00a0al. Positivity for islet cell autoantibodies in patients with monogenic diabetes is associated with later diabetes onset and higher HbA1c level. Diabet Med. 2014;31(4):466\u201371.","journal-title":"Diabet Med"},{"issue":"5","key":"2653_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00125-011-2418-8","volume":"55","author":"BM Shields","year":"2012","unstructured":"Shields\u00a0BM, McDonald\u00a0TJ, Ellard\u00a0S, Campbell\u00a0MJ, Hyde\u00a0C, Hattersley\u00a0AT. The development and validation of a\u00a0clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia. 2012;55(5):1265\u201372.","journal-title":"Diabetologia"},{"issue":"5","key":"2653_CR16","doi-asserted-by":"publisher","first-page":"e00332","DOI":"10.1002\/edm2.332","volume":"5","author":"ST da Silva","year":"2022","unstructured":"da Silva\u00a0ST, Fonseca\u00a0L, Monteiro\u00a0SS, et\u00a0al. MODY probability calculator utility in individuals\u2019 selection for genetic testing: Its accuracy and performance. Endocrinol Diabetes Metab. 2022;5(5):e332.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"2653_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/dc13-0410","volume":"37","author":"RN Naylor","year":"2014","unstructured":"Naylor\u00a0RN, John\u00a0PM, Winn\u00a0AN, et\u00a0al. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014;37(1):202\u20139.","journal-title":"Diabetes Care"},{"issue":"9392","key":"2653_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","volume":"362","author":"ER Pearson","year":"2003","unstructured":"Pearson\u00a0ER, Starkey\u00a0BJ, Powell\u00a0RJ, Gribble\u00a0FM, Clark\u00a0PM, Hattersley\u00a0AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275\u201381.","journal-title":"Lancet"},{"issue":"11","key":"2653_CR19","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.2337\/diacare.26.11.3191-a","volume":"26","author":"M Shepherd","year":"2003","unstructured":"Shepherd\u00a0M, Pearson\u00a0ER, Houghton\u00a0J, Salt\u00a0G, Ellard\u00a0S, Hattersley\u00a0AT. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care. 2003;26(11):3191\u20132.","journal-title":"Diabetes Care"},{"issue":"2","key":"2653_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2337\/diacare.29.02.06.dc05-1314","volume":"29","author":"T Tuomi","year":"2006","unstructured":"Tuomi\u00a0T, Honkanen\u00a0EH, Isomaa\u00a0B, Sarelin\u00a0L, Groop\u00a0LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type\u00a03. Diabetes Care. 2006;29(2):189\u201394.","journal-title":"Diabetes Care"},{"issue":"2","key":"2653_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/EP13254.OR","volume":"20","author":"MK Docena","year":"2014","unstructured":"Docena\u00a0MK, Faiman\u00a0C, Stanley\u00a0CM, Pantalone\u00a0KM. Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy. Endocr Pract. 2014;20(2):107\u201311.","journal-title":"Endocr Pract"},{"issue":"9","key":"2653_CR22","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2337\/db20-0074","volume":"69","author":"AS Christensen","year":"2020","unstructured":"Christensen\u00a0AS, Haedersdal\u00a0S, Storgaard\u00a0H, et\u00a0al. GIP and GLP\u20111 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1alpha mutation carriers. Diabetes. 2020;69(9):1989\u20132002.","journal-title":"Diabetes"},{"issue":"9","key":"2653_CR23","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.2337\/dc20-0408","volume":"43","author":"AS Christensen","year":"2020","unstructured":"Christensen\u00a0AS, Haedersdal\u00a0S, Stoy\u00a0J, et\u00a0al. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type\u00a03): A\u00a0Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). Diabetes Care. 2020;43(9):2025\u201333.","journal-title":"Diabetes Care"},{"issue":"7","key":"2653_CR24","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2337\/dc13-3007","volume":"37","author":"SH Ostoft","year":"2014","unstructured":"Ostoft\u00a0SH, Bagger\u00a0JI, Hansen\u00a0T, et\u00a0al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a\u00a0GLP\u20111 receptor agonist: a\u00a0double-blind, randomized, crossover trial. Diabetes Care. 2014;37(7):1797\u2013805.","journal-title":"Diabetes Care"},{"issue":"9","key":"2653_CR25","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2337\/dc13-0058","volume":"36","author":"S Pruhova","year":"2013","unstructured":"Pruhova\u00a0S, Dusatkova\u00a0P, Neumann\u00a0D, et\u00a0al. Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY? Diabetes Care. 2013;36(9):2573\u20134.","journal-title":"Diabetes Care"},{"issue":"5","key":"2653_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2337\/dc13-2248","volume":"37","author":"AJ Chakera","year":"2014","unstructured":"Chakera\u00a0AJ, Spyer\u00a0G, Vincent\u00a0N, Ellard\u00a0S, Hattersley\u00a0AT, Dunne\u00a0FP. The 0.1\u202f% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort. Diabetes Care. 2014;37(5):1230\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"2653_CR27","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice C.","year":"2022","unstructured":"American Diabetes Association Professional Practice C.. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(1):S17\u2013S38.","journal-title":"Diabetes Care"},{"issue":"7","key":"2653_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2337\/dc14-2769","volume":"38","author":"AJ Chakera","year":"2015","unstructured":"Chakera\u00a0AJ, Steele\u00a0AM, Gloyn\u00a0AL, et\u00a0al. Recognition and management of individuals with hyperglycemia because of a\u00a0heterozygous glucokinase mutation. Diabetes Care. 2015;38(7):1383\u201392.","journal-title":"Diabetes Care"},{"issue":"2","key":"2653_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s001250050666","volume":"40","author":"G Velho","year":"1997","unstructured":"Velho\u00a0G, Blanche\u00a0H, Vaxillaire\u00a0M, et\u00a0al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2\u00a0families. Diabetologia. 1997;40(2):217\u201324.","journal-title":"Diabetologia"},{"issue":"3","key":"2653_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2013.283980","volume":"311","author":"AM Steele","year":"2014","unstructured":"Steele\u00a0AM, Shields\u00a0BM, Wensley\u00a0KJ, Colclough\u00a0K, Ellard\u00a0S, Hattersley\u00a0AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279\u201386.","journal-title":"JAMA"},{"key":"2653_CR31","doi-asserted-by":"publisher","first-page":"802423","DOI":"10.3389\/fendo.2021.802423","volume":"12","author":"J Timsit","year":"2021","unstructured":"Timsit\u00a0J, Ciangura\u00a0C, Dubois-Laforgue\u00a0D, Saint-Martin\u00a0C, Bellanne-Chantelot\u00a0C. Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges. Front Endocrinol. 2021;12:802423.","journal-title":"Front Endocrinol"},{"issue":"2","key":"2653_CR32","doi-asserted-by":"publisher","first-page":"236 e231","DOI":"10.1016\/j.ajog.2015.04.037","volume":"213","author":"S Bacon","year":"2015","unstructured":"Bacon\u00a0S, Schmid\u00a0J, McCarthy\u00a0A, et\u00a0al. The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young. Am J Obstet Gynecol. 2015;213(2):236 e231\u2013236 e237.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2653_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4239\/wjd.v15.i1.15","volume":"15","author":"MS Jeeyavudeen","year":"2024","unstructured":"Jeeyavudeen\u00a0MS, Murray\u00a0SR, Strachan\u00a0MWJ. Management of monogenic diabetes in pregnancy: A\u00a0narrative review. World J Diabetes. 2024;15(1):15\u201323.","journal-title":"World J Diabetes"},{"issue":"3","key":"2653_CR34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2337\/db21-0517","volume":"71","author":"K Colclough","year":"2022","unstructured":"Colclough\u00a0K, Ellard\u00a0S, Hattersley\u00a0A, Patel\u00a0K. Syndromic Monogenic Diabetes Genes Should Be Tested in Patients With a\u00a0Clinical Suspicion of Maturity-Onset Diabetes of the Young. Diabetes. 2022;71(3):530\u20137.","journal-title":"Diabetes"},{"issue":"2","key":"2653_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrneph.2014.232","volume":"11","author":"RL Clissold","year":"2015","unstructured":"Clissold\u00a0RL, Hamilton\u00a0AJ, Hattersley\u00a0AT, Ellard\u00a0S, Bingham\u00a0C. HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum. Nat Rev Nephrol. 2015;11(2):102\u201312.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2653_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00431-015-2675-5","volume":"175","author":"C Reinauer","year":"2016","unstructured":"Reinauer\u00a0C, Meissner\u00a0T, Roden\u00a0M, et\u00a0al. Low prevalence of patients with mitochondrial disease in the German\/Austrian DPV diabetes registry. Eur J Pediatr. 2016;175(5):613\u201322.","journal-title":"Eur J Pediatr"},{"issue":"10","key":"2653_CR37","first-page":"460","volume":"70","author":"HM de Wit","year":"2012","unstructured":"de Wit\u00a0HM, Westeneng\u00a0HJ, van Engelen\u00a0BG, Mudde\u00a0AH. MIDD or MELAS : that\u2019s not the question MIDD evolving into MELAS : a\u00a0severe phenotype of the m.3243A\u3009G mutation due to paternal co-inheritance of type\u00a02 diabetes and a\u00a0high heteroplasmy level. Neth J Med. 2012;70(10):460\u20132.","journal-title":"Neth J Med"},{"key":"2653_CR38","unstructured":"Tuomi T, Miettinen PJ, Hakaste L, Groop L. Atypical Forms of Diabetes. In: De Groot LJ, Chrousos G, Dungan K, et\u00a0al., Hrsg. South Dartmouth: Endotext; 2000."},{"issue":"1","key":"2653_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2015.06.004","volume":"116","author":"AW El-Hattab","year":"2015","unstructured":"El-Hattab\u00a0AW, Adesina\u00a0AM, Jones\u00a0J, Scaglia\u00a0F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015;116(1):4\u201312.","journal-title":"Mol Genet Metab"},{"key":"2653_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-319-95046-4_30","volume":"1085","author":"SH Tsang","year":"2018","unstructured":"Tsang\u00a0SH, Aycinena\u00a0ARP, Mitochondrial Disorder\u00a0ST. Kearns-Sayre Syndrome. Adv Exp Med Biol. 2018;1085:161\u20132.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2653_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000354219","volume":"80","author":"O Rubio-Cabezas","year":"2013","unstructured":"Rubio-Cabezas\u00a0O, Ellard\u00a0S. Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options. Horm Res Paediatr. 2013;80(3):137\u201346.","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"2653_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11154-010-9150-4","volume":"11","author":"IK Temple","year":"2010","unstructured":"Temple\u00a0IK, Shield\u00a0JP. 6q24 transient neonatal diabetes. Rev Endocr Metab Disord. 2010;11(3):199\u2013204.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2653_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1399-5448.2009.00530.x","volume":"11","author":"B Wiedemann","year":"2010","unstructured":"Wiedemann\u00a0B, Schober\u00a0E, Waldhoer\u00a0T, et\u00a0al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian diabetes register. Pediatr Diabetes. 2010;11(1):18\u201323.","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"2653_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11892-011-0234-7","volume":"11","author":"SA Greeley","year":"2011","unstructured":"Greeley\u00a0SA, Naylor\u00a0RN, Philipson\u00a0LH, Bell\u00a0GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011;11(6):519\u201332.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"2653_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clp.2017.10.006","volume":"45","author":"MB Lemelman","year":"2018","unstructured":"Lemelman\u00a0MB, Letourneau\u00a0L, Greeley\u00a0SAW. Neonatal Diabetes Mellitus: An Update on Diagnosis and Management. Clin Perinatol. 2018;45(1):41\u201359.","journal-title":"Clin Perinatol"},{"issue":"4","key":"2653_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/EJE-20-1030","volume":"184","author":"R Bonfanti","year":"2021","unstructured":"Bonfanti\u00a0R, Iafusco\u00a0D, Rabbone\u00a0I, et\u00a0al. Differences between transient neonatal diabetes mellitus subtypes can guide diagnosis and therapy. Eur J Endocrinol. 2021;184(4):575\u201385.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2653_CR47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1056\/NEJMoa055068","volume":"355","author":"AP Babenko","year":"2006","unstructured":"Babenko\u00a0AP, Polak\u00a0M, Cave\u00a0H, et\u00a0al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N\u00a0Engl J Med. 2006;355(5):456\u201366.","journal-title":"N Engl J Med"},{"issue":"3","key":"2653_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/pedi.12823","volume":"20","author":"J Beltrand","year":"2019","unstructured":"Beltrand\u00a0J, Baptiste\u00a0A, Busiah\u00a0K, et\u00a0al. Glibenclamide oral suspension: suitable and effective in patients with neonatal diabetes. Pediatr Diabetes. 2019;20(3):246\u201354.","journal-title":"Pediatr Diabetes"},{"issue":"9996","key":"2653_CR49","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix\u00a0A, Feelders\u00a0RA, Stratakis\u00a0CA, Nieman\u00a0LK. Cushing\u2019s syndrome. Lancet. 2015;386(9996):913\u201327.","journal-title":"Lancet"},{"issue":"11","key":"2653_CR50","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson\u00a0L, Laws\u00a0ER Jr., Melmed\u00a0S, et\u00a0al. Acromegaly: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab. 2014;99(11):3933\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2653_CR51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara\u00a0S, Maffezzoni\u00a0F, Mazziotti\u00a0G, Giustina\u00a0A. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 2016;27(7):470\u201383.","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"2653_CR52","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed\u00a0S, Bronstein\u00a0MD, Chanson\u00a0P, et\u00a0al. A\u00a0Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552\u201361.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2653_CR53","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s12020-025-04202-1","volume":"88","author":"Y Alessi","year":"2025","unstructured":"Alessi\u00a0Y, Alibrandi\u00a0A, Angileri\u00a0FF, Ferrau\u00a0F, Cannavo\u00a0S. Efficacy and safety of pasireotide in patients with Cushing\u2019s disease: a\u00a0monocentric experience. Endocrine. 2025;88(3):820\u20135.","journal-title":"Endocrine"},{"key":"2653_CR54","doi-asserted-by":"publisher","first-page":"1455465","DOI":"10.3389\/fendo.2024.1455465","volume":"15","author":"P Witek","year":"2024","unstructured":"Witek\u00a0P, Bolanowski\u00a0M, Kretowski\u00a0A, Glowinska\u00a0A. Pasireotide-induced hyperglycemia in Cushing\u2019s disease and Acromegaly: A\u00a0clinical perspective and algorithms proposal. Front Endocrinol. 2024;15:1455465.","journal-title":"Front Endocrinol"},{"issue":"15","key":"2653_CR55","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2174\/1389201020666190102145305","volume":"19","author":"C Elena","year":"2018","unstructured":"Elena\u00a0C, Chiara\u00a0M, Angelica\u00a0B, et\u00a0al. Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations. Curr Pharm Biotechnol. 2018;19(15):1210\u201320.","journal-title":"Curr Pharm Biotechnol"},{"issue":"5","key":"2653_CR56","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s13300-023-01393-6","volume":"14","author":"HL Barker","year":"2023","unstructured":"Barker\u00a0HL, Morrison\u00a0D, Llano\u00a0A, Sainsbury\u00a0CAR, Jones\u00a0GC. Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes. Diabetes Ther. 2023;14(5):937\u201345.","journal-title":"Diabetes Ther"},{"issue":"12","key":"2653_CR57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/dom.12739","volume":"18","author":"S Breakey","year":"2016","unstructured":"Breakey\u00a0S, Sharp\u00a0SJ, Adler\u00a0AI, Challis\u00a0BG. Glucocorticoid-induced hyperglycaemia in respiratory disease: a\u00a0systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(12):1274\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2653_CR58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.diabres.2015.02.010","volume":"108","author":"T Katsuyama","year":"2015","unstructured":"Katsuyama\u00a0T, Sada\u00a0KE, Namba\u00a0S, et\u00a0al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015;108(2):273\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5 Pt 2","key":"2653_CR59","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1262-3636(06)72809-9","volume":"32","author":"A Penfornis","year":"2006","unstructured":"Penfornis\u00a0A, Kury-Paulin\u00a0S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006;32(5 Pt 2):539\u201346.","journal-title":"Diabetes Metab"},{"issue":"2","key":"2653_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","volume":"39","author":"DH van Raalte","year":"2009","unstructured":"van Raalte\u00a0DH, Ouwens\u00a0DM, Diamant\u00a0M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39(2):81\u201393.","journal-title":"Eur J Clin Invest"},{"key":"2653_CR61","doi-asserted-by":"crossref","unstructured":"Aberer F, Hochfellner DA, Sourij H, Mader JK. A\u00a0Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. J\u00a0Clin Med. 2021;10(10).","DOI":"10.3390\/jcm10102154"},{"issue":"9","key":"2653_CR62","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2337\/dc12-2441","volume":"36","author":"M Hecking","year":"2013","unstructured":"Hecking\u00a0M, Kainz\u00a0A, Werzowa\u00a0J, et\u00a0al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36(9):2763\u201371.","journal-title":"Diabetes Care"},{"issue":"9","key":"2653_CR63","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/TP.0b013e3181d2fec1","volume":"89","author":"HT Kuo","year":"2010","unstructured":"Kuo\u00a0HT, Sampaio\u00a0MS, Ye\u00a0X, Reddy\u00a0P, Martin\u00a0P, Bunnapradist\u00a0S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the organ procurement and transplant network\/united network for organ sharing database. Transplantation. 2010;89(9):1134\u201340.","journal-title":"Transplantation"},{"issue":"1","key":"2653_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cpt.546","volume":"101","author":"HA Chakkera","year":"2017","unstructured":"Chakkera\u00a0HA, Kudva\u00a0Y, Kaplan\u00a0B. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. Clin Pharmacol Ther. 2017;101(1):114\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2653_CR65","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye\u00a0ES, Castinetti\u00a0F, Criseno\u00a0S, et\u00a0al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187(6):G1\u2013G21.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2653_CR66","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12020-024-04050-5","volume":"87","author":"ER Kani","year":"2025","unstructured":"Kani\u00a0ER, Karaviti\u00a0E, Karaviti\u00a0D, et\u00a0al. Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus. Endocrine. 2025;87(3):875\u201390.","journal-title":"Endocrine"},{"key":"2653_CR67","doi-asserted-by":"crossref","unstructured":"Tankova T, Senkus E, Beloyartseva M, et\u00a0al. Management Strategies for Hyperglycemia Associated with the alpha-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers. 2022;14(7).","DOI":"10.3390\/cancers14071598"},{"issue":"12","key":"2653_CR68","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo\u00a0HS, Lerebours\u00a0F, Ciruelos\u00a0E, et\u00a0al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a\u00a0CDK4\/6 inhibitor (BYLieve): one cohort of a\u00a0phase\u00a02, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629\u2013e38.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2653_CR69","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41598-025-89059-0","volume":"15","author":"JA Lee","year":"2025","unstructured":"Lee\u00a0JA, Lee\u00a0HS, Jeon\u00a0S, et\u00a0al. Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a\u00a0nationwide cohort study. Sci Rep. 2025;15(1):4413.","journal-title":"Sci Rep"},{"issue":"4","key":"2653_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jiac.2016.01.007","volume":"22","author":"K Schulte-Hermann","year":"2016","unstructured":"Schulte-Hermann\u00a0K, Schalk\u00a0H, Haider\u00a0B, et\u00a0al. Impaired lipid profile and insulin resistance in a\u00a0cohort of Austrian HIV patients. J\u00a0Infect Chemother. 2016;22(4):248\u201353.","journal-title":"J Infect Chemother"},{"issue":"128","key":"2653_CR71","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1007\/s00508-015-0939-8","volume":"2","author":"H Abrahamian","year":"2016","unstructured":"Abrahamian\u00a0H, Kautzky-Willer\u00a0A, Riessland-Seifert\u00a0A, et\u00a0al. Mental disorders and diabetes mellitus. Wien Klin Wochenschr. 2016;2(128):S170\u2013S8.","journal-title":"Wien Klin Wochenschr"},{"issue":"9557","key":"2653_CR72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott\u00a0WJ, Meyer\u00a0PM. Incident diabetes in clinical trials of antihypertensive drugs: a\u00a0network meta-analysis. Lancet. 2007;369(9557):201\u20137.","journal-title":"Lancet"},{"key":"2653_CR73","doi-asserted-by":"publisher","first-page":"1239335","DOI":"10.3389\/fendo.2023.1239335","volume":"14","author":"M Laakso","year":"2023","unstructured":"Laakso\u00a0M, Fernandes\u00a0SL. Statins and risk of type\u00a02 diabetes: mechanism and clinical implications. Front Endocrinol. 2023;14:1239335.","journal-title":"Front Endocrinol"},{"issue":"3","key":"2653_CR74","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00592-023-02205-w","volume":"61","author":"W Masson","year":"2024","unstructured":"Masson\u00a0W, Lobo\u00a0M, Barbagelata\u00a0L, Nogueira\u00a0JP. Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk. Acta Diabetol. 2024;61(3):351\u201360.","journal-title":"Acta Diabetol"},{"issue":"5","key":"2653_CR75","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","volume":"27","author":"M Casula","year":"2017","unstructured":"Casula\u00a0M, Mozzanica\u00a0F, Scotti\u00a0L, et\u00a0al. Statin use and risk of new-onset diabetes: A\u00a0meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27(5):396\u2013406.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"2653_CR76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00125-015-3802-6","volume":"59","author":"SJ Livingstone","year":"2016","unstructured":"Livingstone\u00a0SJ, Looker\u00a0HC, Akbar\u00a0T, et\u00a0al. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the collaborative atorvastatin in diabetes trial (CARDS). Diabetologia. 2016;59(2):299\u2013306.","journal-title":"Diabetologia"},{"issue":"5","key":"2653_CR77","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","volume":"12","author":"Cholesterol Treatment Trialists\u2019 Collaboration. Electronic address cnoau","year":"2024","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Electronic address cnoau, Cholesterol Treatment Trialists C.. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2653_CR78","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg\u00a0A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J\u00a0Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2653_CR79","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown\u00a0RJ, Araujo-Vilar\u00a0D, Cheung\u00a0PT, et\u00a0al. The Diagnosis and Management of Lipodystrophy Syndromes: A\u00a0Multi-Society Practice Guideline. J\u00a0Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"2653_CR80","volume-title":"Endotext","author":"B Akinci","year":"2000","unstructured":"Akinci\u00a0B, Sahinoz\u00a0M, Oral\u00a0E. Lipodystrophy Syndromes: Presentation and Treatment. In: Feingold\u00a0KR, Anawalt\u00a0B, Boyce\u00a0A, et\u00a0al., Hrsg. Endotext. South Dartmouth (MA). 2000."},{"issue":"7","key":"2653_CR81","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","volume":"17","author":"PW Mallon","year":"2003","unstructured":"Mallon\u00a0PW, Miller\u00a0J, Cooper\u00a0DA, Carr\u00a0A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971\u20139.","journal-title":"AIDS"},{"issue":"3","key":"2653_CR82","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000329188","volume":"11","author":"Y Cui","year":"2011","unstructured":"Cui\u00a0Y, Andersen\u00a0DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11(3):279\u201394.","journal-title":"Pancreatology"},{"issue":"4","key":"2653_CR83","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/dmrr.2260","volume":"28","author":"N Ewald","year":"2012","unstructured":"Ewald\u00a0N, Kaufmann\u00a0C, Raspe\u00a0A, Kloer\u00a0HU, Bretzel\u00a0RG, Hardt\u00a0PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type\u00a03c). Diabetes Metab Res Rev. 2012;28(4):338\u201342.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"2653_CR84","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/db16-1477","volume":"66","author":"DK Andersen","year":"2017","unstructured":"Andersen\u00a0DK, Korc\u00a0M, Petersen\u00a0GM, et\u00a0al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66(5):1103\u201310.","journal-title":"Diabetes"},{"key":"2653_CR85","doi-asserted-by":"crossref","unstructured":"Schranz A, Sternad C, Aziz F, et\u00a0al. Incidence of Diabetes Mellitus and Its Impact on Outcomes in Patients Undergoing Surgical Pancreatectomy for Non-Malignant and Malignant Pancreatobiliary Diseases\u2014A Retrospective Analysis. J\u00a0Clin Med. 2023;12(24).","DOI":"10.3390\/jcm12247532"},{"issue":"1","key":"2653_CR86","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"AD Association","year":"2014","unstructured":"Association\u00a0AD. Standards of medical care in diabetes\u20142014. Diabetes Care. 2014;37(1):S14\u2013S80.","journal-title":"Diabetes Care"},{"issue":"4","key":"2653_CR87","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s002680020337","volume":"25","author":"LA Slezak","year":"2001","unstructured":"Slezak\u00a0LA, Andersen\u00a0DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25(4):452\u201360.","journal-title":"World J Surg"},{"issue":"42","key":"2653_CR88","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.3748\/wjg.v19.i42.7276","volume":"19","author":"N Ewald","year":"2013","unstructured":"Ewald\u00a0N, Hardt\u00a0PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol. 2013;19(42):7276\u201381.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2653_CR89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejim.2012.12.017","volume":"24","author":"N Ewald","year":"2013","unstructured":"Ewald\u00a0N, Bretzel\u00a0RG. Diabetes mellitus secondary to pancreatic diseases (Type\u00a03c)\u2014are we neglecting an important disease? Eur J Intern Med. 2013;24(3):203\u20136.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2653_CR90","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1089\/dia.2022.0400","volume":"25","author":"G Krutkyte","year":"2023","unstructured":"Krutkyte\u00a0G, Roos\u00a0J, Schuerch\u00a0D, et\u00a0al. Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery. Diabetes Technol Ther. 2023;25(3):206\u201311.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"2653_CR91","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","volume":"18","author":"A Granados","year":"2019","unstructured":"Granados\u00a0A, Chan\u00a0CL, Ode\u00a0KL, Moheet\u00a0A, Moran\u00a0A, Holl\u00a0R. Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J\u00a0Cyst Fibros. 2019;18(2):S3\u2013S9.","journal-title":"J Cyst Fibros"},{"issue":"7","key":"2653_CR92","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1515\/jpem-2019-0484","volume":"33","author":"C Alves","year":"2020","unstructured":"Alves\u00a0C, Della-Manna\u00a0T, Albuquerque\u00a0CTM. Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment. J\u00a0Pediatr Endocrinol Metab. 2020;33(7):835\u201343.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"2653_CR93","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jcf.2019.08.011","volume":"18","author":"BA Kaminski","year":"2019","unstructured":"Kaminski\u00a0BA, Goldsweig\u00a0BK, Sidhaye\u00a0A, Blackman\u00a0SM, Schindler\u00a0T, Moran\u00a0A. Cystic fibrosis related diabetes: Nutrition and growth considerations. J\u00a0Cyst Fibros. 2019;18(2):S32\u2013S7.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"2653_CR94","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran\u00a0A, Brunzell\u00a0C, Cohen\u00a0RC, et\u00a0al. Clinical care guidelines for cystic fibrosis-related diabetes: a\u00a0position statement of the American Diabetes Association and a\u00a0clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697\u2013708.","journal-title":"Diabetes Care"},{"issue":"10","key":"2653_CR95","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00125-024-06223-3","volume":"67","author":"KJ Scully","year":"2024","unstructured":"Scully\u00a0KJ, Marks\u00a0BE, Putman\u00a0MS. Advances in diabetes technology to improve the lives of people with cystic fibrosis. Diabetologia. 2024;67(10):2143\u201353.","journal-title":"Diabetologia"},{"issue":"2","key":"2653_CR96","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","volume":"18","author":"KL Ode","year":"2019","unstructured":"Ode\u00a0KL, Chan\u00a0CL, Granados\u00a0A, Moheet\u00a0A, Moran\u00a0A, Brennan\u00a0AL. Cystic fibrosis related diabetes: Medical management. J\u00a0Cyst Fibros. 2019;18(2):S10\u2013S8.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2653_CR97","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/pedi.12014","volume":"14","author":"M Sunni","year":"2013","unstructured":"Sunni\u00a0M, Bellin\u00a0MD, Moran\u00a0A. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes. 2013;14(4):295\u20138.","journal-title":"Pediatr Diabetes"},{"key":"2653_CR98","first-page":"100375","volume":"38","author":"A Ahmed","year":"2024","unstructured":"Ahmed\u00a0A, Ankireddypalli\u00a0A, Harindhanavudhi\u00a0T, Moran\u00a0A, Moheet\u00a0A. Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A\u00a0cases series and literature review. J\u00a0Clin Transl Endocrinol. 2024;38:100375.","journal-title":"J Clin Transl Endocrinol"},{"issue":"4","key":"2653_CR99","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/nu4040286","volume":"4","author":"BW Balzer","year":"2012","unstructured":"Balzer\u00a0BW, Graham\u00a0CL, Craig\u00a0ME, et\u00a0al. Low glycaemic index dietary interventions in youth with cystic fibrosis: a\u00a0systematic review and discussion of the clinical implications. Nutrients. 2012;4(4):286\u201396.","journal-title":"Nutrients"},{"key":"2653_CR100","doi-asserted-by":"crossref","unstructured":"van der Spek MIVHJ, Jonkerb JW, de Meijerc VE, Bodewes FAJA. Characteristics and outcomes of people with cystic fibrosis on the Eurotransplant liver transplantation waiting list. J\u00a0Cyst Fibros. 2025;.","DOI":"10.1016\/j.jcf.2025.04.005"},{"issue":"8","key":"2653_CR101","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/pedi.13453","volume":"23","author":"KL Ode","year":"2022","unstructured":"Ode\u00a0KL, Ballman\u00a0M, Battezzati\u00a0A, et\u00a0al. ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1212\u201328.","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"2653_CR102","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ueg2.12674","volume":"13","author":"JE Dominguez-Munoz","year":"2025","unstructured":"Dominguez-Munoz\u00a0JE, Vujasinovic\u00a0M, de la Iglesia\u00a0D, et\u00a0al. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United European Gastroenterol\u00a0J. 2025;13(1):125\u201372.","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"2653_CR103","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000049445","volume":"2","author":"PD Hardt","year":"2002","unstructured":"Hardt\u00a0PD, Killinger\u00a0A, Nalop\u00a0J, Schnell-Kretschmer\u00a0H, Zekorn\u00a0T, Klor\u00a0HU. Chronic pancreatitis and diabetes mellitus. A\u00a0retrospective analysis of 156 ERCP investigations in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Pancreatology. 2002;2(1):30\u20133.","journal-title":"Pancreatology"},{"issue":"9","key":"2653_CR104","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1023\/A:1025422423435","volume":"48","author":"PD Hardt","year":"2003","unstructured":"Hardt\u00a0PD, Hauenschild\u00a0A, Jaeger\u00a0C, et\u00a0al. High prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations: a\u00a0prospective multicenter study. Dig Dis Sci. 2003;48(9):1688\u201392.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"2653_CR105","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1055\/s-2001-17867","volume":"39","author":"A Icks","year":"2001","unstructured":"Icks\u00a0A, Haastert\u00a0B, Giani\u00a0G, Rathmann\u00a0W. Low fecal elastase\u20111 in type\u00a0I diabetes mellitus. Z\u00a0Gastroenterol. 2001;39(10):823\u201330.","journal-title":"Z Gastroenterol"},{"issue":"3","key":"2653_CR106","first-page":"211","volume":"25","author":"PG Lankisch","year":"1982","unstructured":"Lankisch\u00a0PG, Manthey\u00a0G, Otto\u00a0J, et\u00a0al. Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion. 1982;25(3):211\u20136.","journal-title":"Digestion"},{"key":"2653_CR107","doi-asserted-by":"publisher","first-page":"595649","DOI":"10.1155\/2015\/595649","volume":"2015","author":"M Piciucchi","year":"2015","unstructured":"Piciucchi\u00a0M, Capurso\u00a0G, Archibugi\u00a0L, Delle Fave\u00a0MM, Capasso\u00a0M, Delle Fave\u00a0G. Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment. Int J Endocrinol. 2015;2015:595649.","journal-title":"Int J Endocrinol"},{"issue":"16","key":"2653_CR108","first-page":"388","volume":"39","author":"G Bretzke","year":"1984","unstructured":"Bretzke\u00a0G. Diabetes mellitus and exocrine pancreas function. Z\u00a0Gesamte Inn Med. 1984;39(16):388\u201390.","journal-title":"Z Gesamte Inn Med"},{"issue":"10","key":"2653_CR109","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/003655201750422657","volume":"36","author":"W Rathmann","year":"2001","unstructured":"Rathmann\u00a0W, Haastert\u00a0B, Icks\u00a0A, et\u00a0al. Low faecal elastase 1 concentrations in type\u00a02 diabetes mellitus. Scand J Gastroenterol. 2001;36(10):1056\u201361.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"2653_CR110","doi-asserted-by":"publisher","first-page":"e0179911","DOI":"10.1371\/journal.pone.0179911","volume":"12","author":"M Lundberg","year":"2017","unstructured":"Lundberg\u00a0M, Lindqvist\u00a0A, Wierup\u00a0N, Krogvold\u00a0L, Dahl-Jorgensen\u00a0K, Skog\u00a0O. The density of parasympathetic axons is reduced in the exocrine pancreas of individuals recently diagnosed with type\u00a01 diabetes. PLoS ONE. 2017;12(6):e179911.","journal-title":"PLoS ONE"},{"issue":"10","key":"2653_CR111","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1089\/ars.2011.4079","volume":"15","author":"M Apte","year":"2011","unstructured":"Apte\u00a0M, Pirola\u00a0R, Wilson\u00a0J. The fibrosis of chronic pancreatitis: new insights into the role of pancreatic stellate cells. Antioxid Redox Signal. 2011;15(10):2711\u201322.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"2653_CR112","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1559-4572.2008.00024.x","volume":"3","author":"MR Hayden","year":"2008","unstructured":"Hayden\u00a0MR, Patel\u00a0K, Habibi\u00a0J, et\u00a0al. Attenuation of endocrine-exocrine pancreatic communication in type\u00a02 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J\u00a0Cardiometab Syndr. 2008;3(4):234\u201343.","journal-title":"J Cardiometab Syndr"},{"issue":"7","key":"2653_CR113","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/MPA.0b013e31821fde3f","volume":"40","author":"D Wu","year":"2011","unstructured":"Wu\u00a0D, Xu\u00a0Y, Zeng\u00a0Y, Wang\u00a0X. Endocrine pancreatic function changes after acute pancreatitis. Pancreas. 2011;40(7):1006\u201311.","journal-title":"Pancreas"},{"issue":"6","key":"2653_CR114","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11892-020-01304-0","volume":"20","author":"B Radlinger","year":"2020","unstructured":"Radlinger\u00a0B, Ramoser\u00a0G, Kaser\u00a0S. Exocrine Pancreatic Insufficiency in Type\u00a01 and Type\u00a02 Diabetes. Curr Diab Rep. 2020;20(6):18.","journal-title":"Curr Diab Rep"},{"key":"2653_CR115","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2019.07.021","volume":"68","author":"E Softeland","year":"2019","unstructured":"Softeland\u00a0E, Poulsen\u00a0JL, Starup-Linde\u00a0J, et\u00a0al. Pancreatic exocrine insufficiency in diabetes mellitus\u2014prevalence and characteristics. Eur J Intern Med. 2019;68:18\u201322.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"2653_CR116","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/MPA.0000000000000609","volume":"45","author":"S Mohapatra","year":"2016","unstructured":"Mohapatra\u00a0S, Majumder\u00a0S, Smyrk\u00a0TC, et\u00a0al. Diabetes Mellitus Is Associated With an Exocrine Pancreatopathy: Conclusions From a\u00a0Review of Literature. Pancreas. 2016;45(8):1104\u201310.","journal-title":"Pancreas"},{"issue":"9","key":"2653_CR117","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/ajg.2017.181","volume":"112","author":"MD Bellin","year":"2017","unstructured":"Bellin\u00a0MD, Whitcomb\u00a0DC, Abberbock\u00a0J, et\u00a0al. Patient and disease characteristics associated with the presence of diabetes mellitus in adults with chronic pancreatitis in the United States. Am J Gastroenterol. 2017;112(9):1457\u201365.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2653_CR118","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2050640616684695","volume":"5","author":"JM Lohr","year":"2017","unstructured":"Lohr\u00a0JM, Dominguez-Munoz\u00a0E, Rosendahl\u00a0J, et\u00a0al. United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (hapanEU). United European Gastroenterol j. 2017;5(2):153\u201399.","journal-title":"United European Gastroenterol j"},{"key":"2653_CR119","doi-asserted-by":"crossref","unstructured":"de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J, Lopez-Lopez A, Nieto L, Dominguez-Munoz JE. Increased Risk of Mortality Associated With Pancreatic Exocrine Insufficiency in Patients With Chronic Pancreatitis. J\u00a0Clin Gastroenterol. 2017;.","DOI":"10.1016\/j.pan.2016.05.270"},{"issue":"1","key":"2653_CR120","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0b013e31820e208e","volume":"53","author":"E Van de Vijver","year":"2011","unstructured":"Van de Vijver\u00a0E, Desager\u00a0K, Mulberg\u00a0AE, et\u00a0al. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. J\u00a0Pediatr Gastroenterol Nutr. 2011;53(1):61\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"2653_CR121","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.pan.2017.09.004","volume":"17","author":"G Roeyen","year":"2017","unstructured":"Roeyen\u00a0G, Jansen\u00a0M, Hartman\u00a0V, et\u00a0al. The impact of pancreaticoduodenectomy on endocrine and exocrine pancreatic function: A\u00a0prospective cohort study based on pre- and postoperative function tests. Pancreatology. 2017;17(6):974\u201382.","journal-title":"Pancreatology"},{"key":"2653_CR122","doi-asserted-by":"crossref","unstructured":"Vujasinovic M, Valente R, Thorell A, et\u00a0al. Pancreatic Exocrine Insufficiency after Bariatric Surgery. Nutrients. 2017;9(11).","DOI":"10.3390\/nu9111241"},{"issue":"5","key":"2653_CR123","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/joim.12745","volume":"283","author":"JM Lohr","year":"2018","unstructured":"Lohr\u00a0JM, Panic\u00a0N, Vujasinovic\u00a0M, Verbeke\u00a0CS. The ageing pancreas: a\u00a0systematic review of the evidence and analysis of the consequences. J\u00a0Intern Med. 2018;283(5):446\u201360.","journal-title":"J Intern Med"},{"issue":"5","key":"2653_CR124","first-page":"867","volume":"92","author":"CE Moran","year":"1997","unstructured":"Moran\u00a0CE, Sosa\u00a0EG, Martinez\u00a0SM, et\u00a0al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol. 1997;92(5):867\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2653_CR125","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.pan.2013.02.008","volume":"13","author":"EC Sikkens","year":"2013","unstructured":"Sikkens\u00a0EC, Cahen\u00a0DL, Koch\u00a0AD, et\u00a0al. The prevalence of fat-soluble vitamin deficiencies and a\u00a0decreased bone mass in patients with chronic pancreatitis. Pancreatology. 2013;13(3):238\u201342.","journal-title":"Pancreatology"},{"issue":"8","key":"2653_CR126","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5694\/j.1326-5377.2010.tb04000.x","volume":"193","author":"J Toouli","year":"2010","unstructured":"Toouli\u00a0J, Biankin\u00a0AV, Oliver\u00a0MR, et\u00a0al. Management of pancreatic exocrine insufficiency: Australasian pancreatic club recommendations. Med J Aust. 2010;193(8):461\u20137.","journal-title":"Med J Aust"},{"issue":"1","key":"2653_CR127","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12876-024-03188-w","volume":"24","author":"JA Barkin","year":"2024","unstructured":"Barkin\u00a0JA, Delk\u00a0TB, Powell\u00a0VJ. Symptoms, burden, and unmet needs of patients living with exocrine pancreatic insufficiency: a\u00a0narrative review of the patient experience. BMC Gastroenterol. 2024;24(1):101.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"2653_CR128","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/MOG.0000000000000951","volume":"39","author":"ML Ramsey","year":"2023","unstructured":"Ramsey\u00a0ML, Hart\u00a0PA, Forsmark\u00a0CE. Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls. Curr Opin Gastroenterol. 2023;39(5):428\u201335.","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"2653_CR129","first-page":"187","volume":"35","author":"C Loser","year":"1997","unstructured":"Loser\u00a0C, Mollgaard\u00a0A, Aygen\u00a0S, Hennemann\u00a0O, Folsch\u00a0UR. 13C-starch breath test\u2014comparative clinical evaluation of an indirect pancreatic function test. Z\u00a0Gastroenterol. 1997;35(3):187\u201394.","journal-title":"Z Gastroenterol"},{"issue":"3","key":"2653_CR130","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/BF00275269","volume":"19","author":"R Ebert","year":"1980","unstructured":"Ebert\u00a0R, Creutzfeldt\u00a0W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia. 1980;19(3):198\u2013204.","journal-title":"Diabetologia"},{"issue":"3","key":"2653_CR131","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/2047-783X-14-3-118","volume":"14","author":"N Ewald","year":"2009","unstructured":"Ewald\u00a0N, Raspe\u00a0A, Kaufmann\u00a0C, Bretzel\u00a0RG, Kloer\u00a0HU, Hardt\u00a0PD. Determinants of exocrine pancreatic function as measured by fecal elastase\u20111 concentrations (FEC) in patients with diabetes mellitus. Eur J Med Res. 2009;14(3):118\u201322.","journal-title":"Eur J Med Res"},{"issue":"5","key":"2653_CR132","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000073655","volume":"3","author":"PD Hardt","year":"2003","unstructured":"Hardt\u00a0PD, Hauenschild\u00a0A, Nalop\u00a0J, et\u00a0al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A\u00a0multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003;3(5):395\u2013402.","journal-title":"Pancreatology"},{"issue":"12","key":"2653_CR133","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1111\/j.1572-0241.2003.08730.x","volume":"98","author":"AC Nunes","year":"2003","unstructured":"Nunes\u00a0AC, Pontes\u00a0JM, Rosa\u00a0A, Gomes\u00a0L, Carvalheiro\u00a0M, Freitas\u00a0D. Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus. Am J Gastroenterol. 2003;98(12):2672\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2653_CR134","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13098-025-01663-2","volume":"17","author":"TT Karaevren","year":"2025","unstructured":"Karaevren\u00a0TT, Yorulmaz\u00a0R, Cerit\u00a0M, et\u00a0al. Fatty pancreas disease in newly diagnosed type\u00a02 diabetes patients: a\u00a0case-control study on relationships with glycemic control and exocrine function. Diabetol Metab Syndr. 2025;17(1):107.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"2653_CR135","doi-asserted-by":"publisher","first-page":"975","DOI":"10.18632\/aging.203854","volume":"14","author":"X Feng","year":"2022","unstructured":"Feng\u00a0X, Li\u00a0XQ. The prevalence of small intestinal bacterial overgrowth in diabetes mellitus: a\u00a0systematic review and meta-analysis. Aging. 2022;14(2):975\u201388.","journal-title":"Aging"},{"issue":"13","key":"2653_CR136","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.ejca.2011.03.003","volume":"47","author":"Q Ben","year":"2011","unstructured":"Ben\u00a0Q, Xu\u00a0M, Ning\u00a0X, et\u00a0al. Diabetes mellitus and risk of pancreatic cancer: A\u00a0meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928\u201337.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2653_CR137","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/MPA.0000000000000721","volume":"46","author":"KL Raphael","year":"2017","unstructured":"Raphael\u00a0KL, Chawla\u00a0S, Kim\u00a0S, et\u00a0al. Pancreatic Insufficiency Secondary to Tobacco Exposure: A\u00a0Controlled Cross-Sectional Evaluation. Pancreas. 2017;46(2):237\u201343.","journal-title":"Pancreas"},{"issue":"1","key":"2653_CR138","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00508-019-1454-0","volume":"131","author":"S Kaser","year":"2019","unstructured":"Kaser\u00a0S, Winhofer-Stockl\u00a0Y, Kazemi-Shirazi\u00a0L, et\u00a0al. Other specific types of diabetes and exocrine pancreatic insufficiency (Update 2019). Wien Klin Wochenschr. 2019;131(1):16\u201326.","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"2653_CR139","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/CMR.0000000000000384","volume":"27","author":"A Tsiogka","year":"2017","unstructured":"Tsiogka\u00a0A, Jansky\u00a0GL, Bauer\u00a0JW, Koelblinger\u00a0P. Fulminant type\u00a01 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017;27(5):524\u20135.","journal-title":"Melanoma Res"},{"issue":"1","key":"2653_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/wjon1085w","volume":"9","author":"A Cheema","year":"2018","unstructured":"Cheema\u00a0A, Makadia\u00a0B, Karwadia\u00a0T, Bajwa\u00a0R, Hossain\u00a0M. Autoimmune Diabetes Associated With Pembrolizumab: A\u00a0Review of Published Case Reports. World J Oncol. 2018;9(1):1\u20134.","journal-title":"World J Oncol"},{"key":"2653_CR141","doi-asserted-by":"crossref","unstructured":"Lee S, Morgan A, Shah S, Ebeling PR. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy. Endocrinol Diabetes Metab Case Rep. 2018;2018.","DOI":"10.1530\/EDM-18-0021"},{"issue":"7","key":"2653_CR142","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/qjmed\/hcl059","volume":"99","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis\u00a0PA, Bakris\u00a0GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99(7):431\u20136.","journal-title":"QJM"},{"issue":"16","key":"2653_CR143","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.286.16.1945","volume":"286","author":"B Luna","year":"2001","unstructured":"Luna\u00a0B, Feinglos\u00a0MN. Drug-induced hyperglycemia. JAMA. 2001;286(16):1945\u20138.","journal-title":"JAMA"},{"issue":"6","key":"2653_CR144","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1097\/CCM.0b013e3181dda0f2","volume":"38","author":"Z Thomas","year":"2010","unstructured":"Thomas\u00a0Z, Bandali\u00a0F, McCowen\u00a0K, Malhotra\u00a0A. Drug-induced endocrine disorders in the intensive care unit. Crit Care Med. 2010;38(6):S219\u2013S30.","journal-title":"Crit Care Med"},{"issue":"2","key":"2653_CR145","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bcp.2014.01.020","volume":"88","author":"A Fuhrmann","year":"2014","unstructured":"Fuhrmann\u00a0A, Lopes\u00a0P, Sereno\u00a0J, et\u00a0al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol. 2014;88(2):216\u201328.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2653_CR146","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.diabet.2017.05.003","volume":"43","author":"B Verges","year":"2017","unstructured":"Verges\u00a0B. Effects of anti-somatostatin agents on glucose metabolism. Diabetes Metab. 2017;43(5):411\u20135.","journal-title":"Diabetes Metab"},{"issue":"1","key":"2653_CR147","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","volume":"53","author":"KD Watt","year":"2010","unstructured":"Watt\u00a0KD, Charlton\u00a0MR. Metabolic syndrome and liver transplantation: a\u00a0review and guide to management. J\u00a0Hepatol. 2010;53(1):199\u2013206.","journal-title":"J Hepatol"},{"issue":"2","key":"2653_CR148","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2011","unstructured":"De Hert\u00a0M, Detraux\u00a0J, van Winkel\u00a0R, Yu\u00a0W, Correll\u00a0CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114\u201326.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02653-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02653-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02653-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:14:40Z","timestamp":1779315280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02653-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":148,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02653-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.\u00a0Kaser hat Vortragshonorare bzw. Beraterhonorare erhalten von Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, Amarin. S.E.\u00a0Hofer hat Vortragshonorare bzw. Beraterhonorare erhalten von E.\u00a0Lilly, Sanofi, Ypsomed. L.\u00a0Kazemi-Shirazi hat folgende Unterst\u00fctzungen\/Honorare bekommen: Past\/present Principal investigator bei Studien gesponsort durch: SigmaTau, Sanofi, Tigenix und Falk; Vortragshonorare erhalten von: MSD, AbbVie, Ferring, Merck Serono\/Dr. Falk, Chiesi, Novartis, Roche, Abbott, Phadia Austria\/Thermo Fisher Scientific, CSL-Behring, Janssen-Cilag Pharma, Labors.at GmbH, Vertex, ENML Laborbetriebs GmbH, Johnson\u00a0& Johnson. Kongressunterst\u00fctzungen von: Mylan, Abbott, MSD, Gilead, Merck Serono\/Dr Falk, Novartis, Pfizer, Janssen-Cilag Pharma, Chiesi, Shire, AbbVie, Takeda, Vertex, Astropharma, Konsulent\/Berater-T\u00e4tigkeit: MSD, Takeda. T.\u00a0Stulnig hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeit oder Forschungsunterst\u00fctzungen erhalten: 89bio, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi. Y.\u00a0Winhofer-St\u00f6ckl hat Vortrags- und Beratungshonorare erhalten von Novo Nordisk, Eli Lilly, Sanofi, Abbott und Dexcom. M.l.\u00a0Resl hat Vortragshonorare bzw. Beraterhonorare von Eli Lilly, Bayer, Abbott, Dexcom und Boehringer Ingelheim erhalten. C.\u00a0Ress hat keine potenziellen Interessenkonflikte. H.\u00a0Sourij gibt folgende Offenlegungen an: Advisory Boards von Amgen, Amarin, Boehringer Ingelheim, Bayer, Eli Lilly, Daiichi Sankyo, Novartis, Novo Nordisk, Sanofi; Honorare f\u00fcr Vortragst\u00e4tigkeit: Amgen, Amarin, Boehringer Ingelheim, Bayer, Eli Lilly, Daiichi Sankyo, Novartis, Novo Nordisk, Sanofi. F.\u00a0Aberer hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeit oder Forschungsunterst\u00fctzungen erhalten: Amgen, Bayer, Sanofi, Novo Nordisk, AstraZeneca und Boehringer Ingelheim. G.\u00a0Treiber hat Vortragshonorare erhalten von Medtronic, Novo Nordisk, Sanofi. A.\u00a0Szodl hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeit oder Forschungsunterst\u00fctzungen erhalten: Sanofi, Novo Nordisk, AstraZeneca, Boehringer Ingelheim und Ascendis Pharma. B.\u00a0Radlinger hat Vortragshonorare von Amgen und Daiichi Sankyo sowie Kongressunterst\u00fctzung von Daiichi Sankyo und Novo Nordisk erhalten. E.\u00a0Binder und A.\u00a0Luger geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}